Evidence map›Paper›PMID 35648122›Full record

ReviewALTEX2023

Beyond pharmaceuticals: Fit-for-purpose new approach methodologies for environmental cardiotoxicity testing.

Mark C Daley, Ulrike Mende, Bum-Rak Choi, Patrick D McMullen, Kareen L K Coulombe

Abstract readReview
In one paragraph

Review in ALTEX, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mark C DaleyCenter for Biomedical Engineering, School of Engineering and Division of Biology and Medicine, Brown University, Providence, RI, USA.
Ulrike MendeCardiovascular Research Center, Cardiovascular Institute, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI, USA.
Bum-Rak ChoiCardiovascular Research Center, Cardiovascular Institute, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI, USA.
Patrick D McMullenScitoVation, Durham, NC, USA.
Kareen L K CoulombeCenter for Biomedical Engineering, School of Engineering and Division of Biology and Medicine, Brown University, Providence, RI, USA.

Funding

Human 3D Microtissues for Toxicity Testing via Integrated Imaging, Molecular and Functional AnalysesU01ES028184 · NIEHS · BROWN UNIVERSITY · PI BOEKELHEIDE, KIM, MORGAN, JEFFREY R · 2017 to 2021
$3.8M
NIEHS NIH HHS U01 ES028184
6 · The paper itself

Abstract

Environmental factors play a substantial role in determining cardiovascular health, but data informing the risks presented by environmental toxicants is insufficient. In vitro new approach methodologies (NAMs) offer a promising approach with which to address the limitations of traditional in vivo and in vitro assays for assessing cardiotoxicity. Driven largely by the needs of pharmaceutical toxicity testing, considerable progress in developing NAMs for cardiotoxicity analysis has already been made. As the scientific and regulatory interest in NAMs for environmental chemicals continues to grow, a thorough understanding of the unique features of environmental cardiotoxicants and their associated cardiotoxicities is needed. Here, we review the key characteristics of as well as important regulatory and biological considerations for fit-for-purpose NAMs for environmental cardiotoxicity. By emphasizing the challenges and opportunities presented by NAMs for environmental cardiotoxicity we hope to accelerate their development, acceptance, and application.

Indexed as

CardiotoxicityInduced Pluripotent Stem CellsHumansMyocytes, CardiacPharmaceutical PreparationsToxicity TestsPharmaceutical Preparationsarrhythmiacardiac tissue engineeringhERG assayhiPSC-cardiomyocytesIVIVE

Identifiers

PMID35648122
PMCPMC10502740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.